We’re excited to introduce you to the always interesting and insightful Aryan Govil. We hope you’ll enjoy our conversation with Aryan below.

Hi Aryan, thanks for joining us today. One of the things we most admire about small businesses is their ability to diverge from the corporate/industry standard. Is there something that you or your brand do that differs from the industry standard? We’d love to hear about it as well as any stories you might have that illustrate how or why this difference matters.

The engineering team at Synaptrix Labs makes regular visits to clinics to engage with therapists and patients. Surprisingly, this practice represents a significant departure from the norm in the assistive technology and biotech industries at large. Often, executives and engineers presume they understand patients’ needs and assume their solution is the optimal one. However, our experiences have shown that this assumption is often incorrect. The ability to engage directly with patients, incorporating their feedback into the development process, has proven to be pivotal in shaping our technologies.

Patients offer invaluable insights and perspectives on the unique challenges they face due to their conditions, which our engineers may not have anticipated independently. This iterative process of interaction and refinement has been fundamental to the development of our products. I believe the broader industry can benefit from this approach, prioritizing the creation of solutions that truly align with patients’ needs, rather than relying solely on assumptions.

Great, appreciate you sharing that with us. Before we ask you to share more of your insights, can you take a moment to introduce yourself and how you got to where you are today to our readers.

One thing that has always troubled me is the tendency for research to be conducted primarily for publication in prestigious journals rather than for the benefit of patients. I mention this not to diminish the hard work of researchers worldwide, but to question certain priorities. My aim with Synaptrix and our innovative brain-computer interfaces is to ensure that our solutions prioritize patients and reach them as swiftly as possible.

For many years, I dedicated myself to pioneering clinical trials at NYU Grossman School of Medicine, focusing on various facets of Alzheimer’s Disease. I was particularly intrigued by how principles from computational neuroscience and AI could enhance the clinical outcomes of our patients. Previous experiences at Columbia University and UC Irvine underscored for me the significant impact novel technology, especially AI, can have on healthcare. In my view, neuromodulation through brain-computer interfaces represents the future of disease diagnosis and treatment, surpassing traditional pharmacological approaches.

At Synaptrix Labs, our primary focus is on advancing the next generation of foundational AI models for neural signal processing, alongside developing innovative therapeutics utilizing these models. Emphasizing software development initially has enabled us to construct robust AI models for tasks such as signal de-noising and feature extraction from raw brain signals. We are excited to integrate these models into devices that directly assist patients, while also providing them to others for further development and innovation.

We’d love to hear about how you met your business partner.

I consider myself incredibly fortunate to have an outstanding team supporting me at Synaptrix Labs. Additionally, I am grateful for the longstanding friendship I share with my co-founder, which predates our decision to establish the company together. Eric Yao, my co-founder and the Chief Technology Officer at Synaptrix, has been a tremendous source of inspiration, not only for me but also for the team under his guidance.

Despite Eric’s background in finance rather than medical devices or biotechnology, his profound understanding of deep learning architecture and his ability to develop innovative AI models from scratch have been invaluable assets to our company. Furthermore, he swiftly acquired the necessary knowledge of neuroscience to effectively lead our engineering teams. It’s worth noting that both financial models and neural signals can be understood as time series data—an aspect that people often overlook!

What do you think helped you build your reputation within your market?

Overcoming age bias remains a challenge for our founding team, given our relatively young age. Nonetheless, I strongly advocate for valuing merit and the ability to execute over superficial titles, often collected like badges. We are immensely grateful for the support of exceptional advisors, such as Nobel Prize laureate Dr. Walter Gilbert, recognized for his groundbreaking work in DNA synthesis, and the former Chief Technology Officer of Blackrock Neurotech, a key player in the development of brain-computer interfaces.

Additionally, we benefit from the expertise of world-renowned AI and signal processing experts from institutions like MIT and NYU. Synaptrix is privileged to receive guidance from advisors who possess both internationally acclaimed scientific knowledge and hands-on clinical experience. Their collective wisdom and insights, complemented by their diverse backgrounds, drive Synaptrix forward in developing neural interface technologies that have the potential to profoundly impact lives.

The shared dedication of our advisors to improving lives unifies their varied experiences into a cohesive force that empowers Synaptrix to fulfill its mission.

Contact Info:

• Website: https://synaptrix-labs.com/
• Instagram: https://www.instagram.com/synaptrix_labs/
• Linkedin: https://www.linkedin.com/company/synaptrix-labs
• Twitter: https://x.com/synaptrixai